ZTS
ZTS
NYSE · Pharmaceuticals

Zoetis Inc

S&P 500 Large-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks
$126.89
-0.39 (-0.31%)
As of Feb 21, 12:06 AM ET ·
Financial Highlights (FY 2026)
Revenue
9.64B
Net Income
2.72B
Gross Margin
71.9%
Profit Margin
28.2%
Rev Growth
+5.4%
D/E Ratio
2.72
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 71.9% 71.9% 28.1% 28.1%
Operating Margin 35.5% 31.9% 32.3% 33.9%
Profit Margin 28.2% 26.8% 25.1% 28.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 9.64B 9.15B 12.02B 10.95B
Gross Profit 6.93B 6.57B 3.38B 3.08B
Operating Income 3.42B 2.92B 3.88B 3.71B
Net Income 2.72B 2.32B 3.02B 3.10B
Gross Margin 71.9% 71.9% 28.1% 28.1%
Operating Margin 35.5% 31.9% 32.3% 33.9%
Profit Margin 28.2% 26.8% 25.1% 28.3%
Rev Growth +5.4% +5.4% +1.9% +24.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 20.97B 20.97B 18.38B 22.65B
Total Equity 7.72B 7.72B 33.02B 33.90B
D/E Ratio 2.72 2.72 0.56 0.67
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 3.73B 3.36B 4.97B 3.99B
Free Cash Flow — — 2.28B 2.09B